ホルモン不応性(去勢抵抗性、アンドロゲン非依存性)前立腺がん(Hormone Refractory Prostate Cancer):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014
◆商品コード:GMDHC5680IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:311
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるホルモン不応性(去勢抵抗性、アンドロゲン非依存性)前立腺がん(Hormone Refractory Prostate Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・ホルモン不応性(去勢抵抗性、アンドロゲン非依存性)前立腺がん(Hormone Refractory Prostate Cancer)の概要
・ホルモン不応性(去勢抵抗性、アンドロゲン非依存性)前立腺がん(Hormone Refractory Prostate Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・ホルモン不応性(去勢抵抗性、アンドロゲン非依存性)前立腺がん(Hormone Refractory Prostate Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・ホルモン不応性(去勢抵抗性、アンドロゲン非依存性)前立腺がん(Hormone Refractory Prostate Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・ホルモン不応性(去勢抵抗性、アンドロゲン非依存性)前立腺がん(Hormone Refractory Prostate Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H2 2014’, provides an overview of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Overview 12
Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Comparative Analysis 13
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Therapeutics under Development by Companies 14
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Therapeutics under Investigation by Universities/Institutes 19
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Products under Development by Companies 24
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Products under Investigation by Universities/Institutes 30
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Companies Involved in Therapeutics Development 31
A. Menarini Industrie Farmaceutiche Riunite Srl 31
Adamis Pharmaceuticals Corporation 32
Aeterna Zentaris Inc. 33
Alethia Biotherapeutics Inc. 34
Amgen Inc. 35
AnGes MG, Inc. 36
Antoxis Limited 37
Aphios Corporation 38
Armour Therapeutics Inc. 39
Arno Therapeutics, Inc. 40
Astellas Pharma Inc. 41
Astex Pharmaceuticals, Inc. 42
AstraZeneca PLC 43
Ausio Pharmaceuticals, LLC 44
Bavarian Nordic A/S 45
Bayer AG 46
Beta Pharma, Inc. 47
Bio-Cancer Treatment International Limited 48
Biscayne Pharmaceuticals, Inc. 49
Boehringer Ingelheim GmbH 50
Celldex Therapeutics, Inc. 51
CureTech Ltd. 52
CytoVac A/S 53
DexTech Medical AB 54
Enceladus Pharmaceuticals BV 55
Endo Pharmaceuticals Inc. 56
EndoCeutics, Inc. 57
Endocyte, Inc. 58
Errant Gene Therapeutics, LLC 59
Fujifilm Corporation 60
Genentech, Inc. 61
Glactone Pharma AB 62
GlaxoSmithKline plc 63
GTx, Inc. 64
Harbor Therapeutics, Inc. 65
Hybrigenics S.A. 66
Incuron, LLC 67
Io Therapeutics, Inc. 68
Isis Pharmaceuticals, Inc. 69
Johnson & Johnson 70
Kinex Pharmaceuticals, LLC 71
Medivation, Inc. 72
Medvio Eurasia 73
Merck KGaA 74
Millennium Pharmaceuticals, Inc. 75
NewLink Genetics Corporation 76
Novartis AG 77
Oncogenex Pharmaceuticals, Inc. 78
Orion Oyj 79
Orphagen Pharmaceuticals, Inc. 80
Oxford BioMedica plc 81
Panacela Labs, Inc. 82
Tokai Pharmaceuticals, Inc. 83
Viamet Pharmaceuticals, Inc. 84
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Therapeutics Assessment 85
Assessment by Monotherapy Products 85
Assessment by Target 86
Assessment by Mechanism of Action 90
Assessment by Route of Administration 93
Assessment by Molecule Type 95
Drug Profiles 97
AB-3A4 – Drug Profile 97
afatinib – Drug Profile 98
AKAGU-52 – Drug Profile 102
Alecsat – Drug Profile 103
alisertib – Drug Profile 105
AM-0010 – Drug Profile 109
AMG-212 – Drug Profile 110
AMPI-109 – Drug Profile 112
AO-1530 – Drug Profile 113
apatorsen – Drug Profile 114
APH-0701 – Drug Profile 116
AT-001 – Drug Profile 117
AUS-131 – Drug Profile 118
AZD-3965 – Drug Profile 120
AZD-8186 – Drug Profile 121
BAY-1024767 – Drug Profile 122
BCT-100 – Drug Profile 123
BIS-1602 – Drug Profile 125
BPI-5143 – Drug Profile 126
buparlisib hydrochloride – Drug Profile 127
CG-1521 – Drug Profile 131
CIM-1 – Drug Profile 132
Dendritic Cell Therapy to Target Mucin 1 for Prostatic Adenocarcinoma – Drug Profile 133
DendriVax – Drug Profile 134
dexamethasone acetate – Drug Profile 135
EC-1169 – Drug Profile 136
EM-5854 – Drug Profile 137
EN-3356 – Drug Profile 138
enzalutamide – Drug Profile 139
EPI-001 – Drug Profile 142
galeterone – Drug Profile 143
GEN-0101 – Drug Profile 145
GPA-500 – Drug Profile 147
GPA-512 – Drug Profile 148
GPB-600 – Drug Profile 149
GSK-2849330 – Drug Profile 150
GTx-758 – Drug Profile 151
HE-3235 – Drug Profile 152
HyperAcute Vaccine for Prostate Cancer – Drug Profile 154
inecalcitol – Drug Profile 155
ipatasertib – Drug Profile 157
IRX-4204 – Drug Profile 159
ISIS-EIF4ERx – Drug Profile 161
ITK-1 – Drug Profile 163
JNJ-56021927 – Drug Profile 165
KRM-20 – Drug Profile 167
KX-01 – Drug Profile 168
LFA-102 – Drug Profile 170
mepacrine – Drug Profile 172
MIA-602 – Drug Profile 174
MSB-0010718C – Drug Profile 175
MVA-BN-PRO – Drug Profile 176
MVI-118 – Drug Profile 177
ODM-201 – Drug Profile 178
onalespib – Drug Profile 180
onapristone ER – Drug Profile 183
Oncolytic Virus for Glioblastoma Multiforme and Prostate Cancer – Drug Profile 185
ozarelix – Drug Profile 186
pasireotide LAR – Drug Profile 188
Peptide for Androgen-Independent Prostate Cancer – Drug Profile 190
pidilizumab – Drug Profile 191
radium Ra 223 dichloride – Drug Profile 193
rilotumumab – Drug Profile 196
sabarubicin – Drug Profile 198
Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer – Drug Profile 200
Small Molecule to Inhibit Androgen Receptor for Hormone Refractory Prostate Cancer – Drug Profile 201
Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer – Drug Profile 202
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing’s Disease – Drug Profile 203
Small Molecules to Inhibit AKR1C3 for Oncology – Drug Profile 204
solitomab – Drug Profile 205
Somadex – Drug Profile 207
SR-16388 – Drug Profile 208
TeloB-VAX – Drug Profile 210
TroVax – Drug Profile 211
vandetanib – Drug Profile 214
varlilumab – Drug Profile 220
VT-464 – Drug Profile 222
zoptarelin doxorubicin – Drug Profile 223
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Recent Pipeline Updates 225
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Dormant Projects 289
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Discontinued Products 294
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Product Development Milestones 296
Featured News & Press Releases 296
Appendix 305
Methodology 305
Coverage 305
Secondary Research 305
Primary Research 305
Expert Panel Validation 305
Contact Us 306
Disclaimer 306

[List of Tables]
Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2014 17
Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 20
Number of Products under Development by Companies, H2 2014 (Contd..1) 21
Number of Products under Development by Companies, H2 2014 (Contd..2) 22
Number of Products under Development by Companies, H2 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2014 24
Comparative Analysis by Late Stage Development, H2 2014 25
Comparative Analysis by Clinical Stage Development, H2 2014 26
Comparative Analysis by Early Stage Development, H2 2014 27
Comparative Analysis by Unknown Stage Development, H2 2014 28
Products under Development by Companies, H2 2014 29
Products under Development by Companies, H2 2014 (Contd..1) 30
Products under Development by Companies, H2 2014 (Contd..2) 31
Products under Development by Companies, H2 2014 (Contd..3) 32
Products under Development by Companies, H2 2014 (Contd..4) 33
Products under Investigation by Universities/Institutes, H2 2014 35
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 36
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 37
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aeterna Zentaris Inc., H2 2014 38
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2014 39
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc., H2 2014 40
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AnGes MG, Inc., H2 2014 41
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Antoxis Limited, H2 2014 42
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aphios Corporation, H2 2014 43
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Armour Therapeutics Inc., H2 2014 44
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H2 2014 45
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astellas Pharma Inc., H2 2014 46
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 47
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca PLC, H2 2014 48
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ausio Pharmaceuticals, LLC, H2 2014 49
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 50
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bayer AG, H2 2014 51
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Beta Pharma, Inc., H2 2014 52
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bio-Cancer Treatment International Limited, H2 2014 53
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2014 54
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 55
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2014 56
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureTech Ltd., H2 2014 57
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CytoVac A/S, H2 2014 58
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H2 2014 59
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H2 2014 60
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endo Pharmaceuticals Inc., H2 2014 61
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by EndoCeutics, Inc., H2 2014 62
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endocyte, Inc., H2 2014 63
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Errant Gene Therapeutics, LLC, H2 2014 64
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Fujifilm Corporation, H2 2014 65
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H2 2014 66
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2014 67
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 68
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H2 2014 69
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Harbor Therapeutics, Inc., H2 2014 70
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Hybrigenics S.A., H2 2014 71
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Incuron, LLC, H2 2014 72
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Io Therapeutics, Inc., H2 2014 73
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 74
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H2 2014 75
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H2 2014 76
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H2 2014 77
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medvio Eurasia, H2 2014 78
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Merck KGaA, H2 2014 79
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 80
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H2 2014 81
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H2 2014 82
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2014 83
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orion Oyj, H2 2014 84
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2014 85
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oxford BioMedica plc, H2 2014 86
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Panacela Labs, Inc., H2 2014 87
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals, Inc., H2 2014 88
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viamet Pharmaceuticals, Inc., H2 2014 89
Assessment by Monotherapy Products, H2 2014 90
Number of Products by Stage and Target, H2 2014 92
Number of Products by Stage and Mechanism of Action, H2 2014 96
Number of Products by Stage and Route of Administration, H2 2014 99
Number of Products by Stage and Molecule Type, H2 2014 101
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2014 230
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H2 2014 294
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H2 2014 299
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..1), H2 2014 300

[List of Figures]
Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2014 17
Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 19
Number of Products under Investigation by Universities/Institutes, H2 2014 24
Comparative Analysis by Late Stage Development, H2 2014 25
Comparative Analysis by Clinical Stage Development, H2 2014 26
Comparative Analysis by Early Stage Products, H2 2014 27
Assessment by Monotherapy Products, H2 2014 90
Number of Products by Top 10 Targets, H2 2014 91
Number of Products by Stage and Top 10 Targets, H2 2014 91
Number of Products by Top 10 Mechanism of Actions, H2 2014 95
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 95
Number of Products by Top 10 Routes of Administration, H2 2014 98
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 99
Number of Products by Top 10 Molecule Types, H2 2014 100
Number of Products by Stage and Top 10 Molecule Types, H2 2014 101

【掲載企業】

A. Menarini Industrie Farmaceutiche Riunite Srl
Adamis Pharmaceuticals Corporation
Aeterna Zentaris Inc.
Alethia Biotherapeutics Inc.
Amgen Inc.
AnGes MG, Inc.
Antoxis Limited
Aphios Corporation
Armour Therapeutics Inc.
Arno Therapeutics, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca PLC
Ausio Pharmaceuticals, LLC
Bavarian Nordic A/S
Bayer AG
Beta Pharma, Inc.
Bio-Cancer Treatment International Limited
Biscayne Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Celldex Therapeutics, Inc.
CureTech Ltd.
CytoVac A/S
DexTech Medical AB
Enceladus Pharmaceuticals BV
Endo Pharmaceuticals Inc.
EndoCeutics, Inc.
Endocyte, Inc.
Errant Gene Therapeutics, LLC
Fujifilm Corporation
Genentech, Inc.
Glactone Pharma AB
GlaxoSmithKline plc
GTx, Inc.
Harbor Therapeutics, Inc.
Hybrigenics S.A.
Incuron, LLC
Io Therapeutics, Inc.
Isis Pharmaceuticals, Inc.
Johnson & Johnson
Kinex Pharmaceuticals, LLC
Medivation, Inc.
Medvio Eurasia
Merck KGaA
Millennium Pharmaceuticals, Inc.
NewLink Genetics Corporation
Novartis AG
Oncogenex Pharmaceuticals, Inc.
Orion Oyj
Orphagen Pharmaceuticals, Inc.
Oxford BioMedica plc
Panacela Labs, Inc.
Tokai Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ホルモン不応性(去勢抵抗性、アンドロゲン非依存性)前立腺がん(Hormone Refractory Prostate Cancer):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆